MIRAPEX.com: Combination Therapy with MIRAPEX

Mirapex Benefits

Initial Monotherapy

Combination Therapy

Safety And Dosing

How PD Diagnosed

How PD Diagnosed

How PD Diagnosed

How PD Diagnosed

How PD Diagnosed

Improves functioning in advanced disease^2,3,20

MIRAPEX improves "on" time, reduces "off" time, and improves UPDRS ADL* scores^2,3,20

Controls tremor—including levodopa-resistant tremor⁷

MIRAPEX significantly improves UPDRS tremor and ADL scores⁷

Reduces the use of levodopa^3,21

MIRAPEX helps to reduce the dose of levodopa^3,21

Reduces therapy-related complications^2,3

MIRAPEX statistically improves UPDRS IV scores, a measure of dyskinesia and "off" time^2,3

Learn how combination therapy with MIRAPEX improves patient functioning

*UPDRS=Unified Parkinson’s Disease Rating Scale; ADL=activities of daily living.

Important information about MIRAPEX:

Mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur.
The most commonly reported adverse events in early and late disease in clinical trials were dizziness, dyskinesia, extrapyramidal syndrome, hallucinations, headache, insomnia, somnolence, and nausea.

Patients and caregivers should be informed that impulse control disorders/compulsive behaviors may occur while taking medicines, including pramipexole, to treat Parkinson's disease.

Please see full Prescribing Information.

This information is intended for US residents only.

Terms of Use Privacy Statement

Copyright © 2007 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
Use of this site is subject to the Internet Site Legal Notices and Disclaimers and Privacy Policy.